LONG TERM COMPLICATIONS FOLLOWING PERCUTANEOUS ASD CLOSURE
|
|
- Cody Chandler
- 5 years ago
- Views:
Transcription
1 LONG TERM COMPLICATIONS FOLLOWING PERCUTANEOUS ASD CLOSURE Zakaria Jalal Cardiopathies congénitales de l enfant et de l adulte Hôpital cardiologique Haut Lévêque Pessac CHU Bordeaux
2 INTRODUCTION Percutaneous closure currently preferred treatment for sasd Effective, high success rate, avoidance of surgical complications Amplatzer Septal Occluder = most widely used device Low short term adverse event rates Rare but potentially serious delayed complications Kotowycz et al. JACC Intrv 2012 Abaci et al. CCI 2013
3 DELAYED COMPLICATIONS Cardiac Erosion Device thrombosis Valvular failure AV Conduction abnormalities Nickel allergy Stroke Endocarditis Atrial arrhythmias
4 CARDIAC EROSION Incidence: 0.04 to 0.28% - underestimated ASO >> CardioSeal/Starflex Atrial dome adjacent aorta Perforation, tamponnade, aortic fistula Surgical (3/4) or medical (1/4) management Amin et al. CCI 2004 DiBardino et al. JTCS 2009 FDA Circulatory System Advisory Panel Meeting 2012
5 Moore J. et al. JACC Interv 2013 Kiab et al. CCI 2012 CARDIAC EROSION - PATHOPHYSIOLOGY Risk factors : Absent or deficient aortic rim Device oversizing Protrusion of the device into atrial and/or aortic wall Flaring of the device around the aortic root Delayed erosion: Oversized device - > recover nominal size Flat profile of the discs Increase in diameter Shearing of the atrial wall/aorta
6 CARDIAC EROSION ECHOGRAPHIC Before closure Poor posterior rim consistency Absence of aortic rim in multiple views Septal mal-alignment Dynamic ASD After closure Tenting of the atrial free wall in the transverse sinus Wedging of the discs between posterior wall and aorta Pericardial effusion Amin et al. CCI 2014
7 CARDIAC EROSION - RECOMMENDATIONS Follow-up of patients: 1 week, 1 month, 6 months and yearly Mandatory device tracking Instructions for use: in the patient and physician labeling a warning regarding patient symptoms that require emergent treatment (e.g., severe chest pain) Standard training of echocardiographers, during device closure and follow-up Patient notifications: additional measures to ensure that patients are well informed of the risks/benefits of transcatheter ASD closure, Education ducate about symptoms Moore J. et al. JACC Interv 2013 Kiab et al. CCI 2012 FDA Circulatory System Advisory Panel Meeting 2012
8 DEVICE THROMBOSIS Metaanalysis of 28,142 pts 203 studies Thrombus incidence : 1.0% (95% CI: %) Review Frankfurt experience ASO << CardioSeal, Starflex, or Helex Up to 2 years after closure Coagulopathies, post procedural AF Strokes: 10-15%, no death Medical management vs surgical explantation Sherman et al. CCI 2004 Krumsdorf et al. JACC 2004 Delaney et al. Congenit Heart Dis Abaci et al. CCI 2013
9 DEVICE THROMBOSIS Healing response of the device Biocompatibility - preclinical animal studies No human studies on endothelialization duration Clinical practice: ASA at least 6 months Incomplete endothelialization 18 m - 7 yrs Confirming complete endothelialization? Chessa et al. Int J Cardiol 2004 Chen et al. Circulation 2011 Thomsen et al. Heart 1998
10 STROKE Metaanalysis of 28,142 pts 203 studies Cerebrovascular events 1.1% (95% CI: %) Danish registry 1167 pts percutaneous closure 47 ± 3 yo Median FU: 5.2 years Stroke > for patients with ASD before/after closure No difference with surgical closure Independant risk factors Device thrombosis AF Kutty et al. Am J Cardiol Abaci et al. CCI 2013 Nyboe et al. Heart 2015
11 ATRIAL ARRHYTHMIAS Metaanalysis 945 pts FU: 30 days 5 years Beneficial effect on pre-existing AF Danish registry 300 pts, FU: 5.2 years No pre-existing atrial arrhytmia Higher risk of new onset of AF - adjusted HR 8.2 (95% CI 6.6 to 10.2) Vecht et al. Heart 2010 Nyboe et al. Heart 2015
12 LATE CONDUCTION ABNORMALITIES 5 cases of delayed cavb Age: 2 16 yo, delay: 6m 4yrs ASO (n=4), Helex (n=1) Early changes -> deterioration of conduction 1 surgical explantation Careful long term cardiac rhythm monitoring Consider device removal in case of early conducting abnormalities resistant to medical management PM implantation Szkutnik et al. Cardiol J 2008 Nehgme et al. Pediatr Cardiol 2009 Dittrich et al. CCI 2015
13 VALVULAR DAMAGE MITRAL REGURGITATION Onset or increase 10% pts Usually trivial to moderate No impact on functional status or prognosis Hypotheses: Alterations of atrial function, stiffness Geometric changes of the left heart Annulus echographic geometric changes N= years ASO device Hiraishi et al. Int Heart Jour 2015 Wilson et al. Heart Lung 2008
14 VALVULAR DAMAGE AORTIC REGURGITATION Schoen et al. 70 pts, ASO (57%) and Cardia (43%) devices 16% patients had pre-existing mild AR Novel or worsened AR in 9% of patients Traction at the non-coronary aortic valve sinus Sadiq et al. 200 pts ASO, Mild AR occurred in 1% correlated with a device-to-defect ratio of >1.3:1 Mayo Clinic Series 118 pts, ASO (88%), Helex (12) Mean FU=1.2 years New or worsening AR = 0.8% (1/118) Schoen et al. Heart 2008 Sadiq et al. Cardiol Young 2012 Loar et al. CCI 2013
15 INFECTIVE ENDOCARDITIS 5 cases in the literature, aged from 4 to 60 years ASO involved in all cases From 11 months up to 4 years after implantation Staphylococcus aureus in all but one case One patient: periodontal scaling without antibiotic prophylaxis 1 month before IE Surgical removal of the device in 3 cases: Incomplete endothelialization No endocarditis related death Slesnick et al. Circulation 2008 Zahr et al. Am J Cardiol 2010 Kim et al. Circulation 2015 Incomplete endothelialization No specific method for confirming complete endothelialization Duration of ASA based on animal studies? Duration of IE prophylaxis?
16 Wertman et al. JACC 2006 Rodés-Cabau et al. AJC 2008 NICKEL ALLERGY Nitinol = Titanium 45% + Nickel 55% Symptoms Migraine Headache Chest discomfort Rash/urticaria Fever Pericardial effusion tamponnade Nickel bloodstream release up to 12 months after closure with ASO
17 NICKEL ALLERGY Local inflammatory reaction Platelet adhesion Microemboli Cerebral infarcts PATHOPHYSIOLOGY Inflammatory mediators LA release Calcitonin gene related peptide levels Symptoms may persist for several months Good response to medical management Clopidogrel Antihistamin Antiinflammatory Corticosteroids Rarely: surgical explantation Symptoms Wei et al. Headache 2012 Ries et al. Am Heart J 2003
18 CONCLUSION Percutaneous ASD closure safe and effective using a great number of devices Long-term complications rate is not null Although rare, some of these can be sudden and potentially lethal Both operators and patients need to be aware of these issues Long-term follow-up is mandatory in order to detect these complications
Glenmark Cardiac Centre Mumbai, India
ASD device closure: Long term follow up Bharat Dalvi, MD Glenmark Cardiac Centre Mumbai, India Our experience 1998 to 2011 1566 patients 912 patients > 4 years FU Exclusive with ASO Clinical, electrocardiographic
More informationAtrial Septal Defect
S. Hascoët Cardiologie pédiatrique et congénitale Hôpital Marie lannelongue Atrial Septal Defect long-term follow-up after closure Groupe de travail sur le cathétérisme Cardiaque et congénital Disclosure
More informationPercutaneous ASD closure
S. Hascoët Cardiologie pédiatrique et congénitale Hôpital Marie lannelongue Percutaneous ASD closure Marie Lannelongue Hospital long-term follow-up Groupe de travail sur le cathétérisme Cardiaque et congénital
More informationCONGENITAL HEART DEFECTS IN ADULTS
CONGENITAL HEART DEFECTS IN ADULTS THE ROLE OF CATHETER INTERVENTIONS Mario Carminati CONGENITAL HEART DEFECTS IN ADULTS CHD in natural history CHD with post-surgical sequelae PULMONARY VALVE STENOSIS
More informationBASIL D. THANOPOULOS MD, PhD Associate Professor Honorary Consultant, RBH, London, UK
TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D. THANOPOULOS MD, PhD Associate Professor Honorary Consultant, RBH, London, UK TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D.
More informationFermeture percutanée des CIA : matériels disponibles et résultats. Transcatheter closure of ASD : devices and results
Fermeture percutanée des CIA : matériels disponibles et résultats Transcatheter closure of ASD : devices and results François Godart, University of Lille 2, France 12 e Congrès Médico-Chirurgical de la
More informationAtrial Septal Defect Closure. Stephen Brecker Director, Cardiac Catheterisation Labs
Stephen Brecker Director, Cardiac Catheterisation Labs ADVANCED ANGIOPLASTY Incorporating The Left Main 5 Plus Course Conflicts of Interest The following companies have supported educational courses held
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Alagille syndrome, pulmonary artery stenosis in, 143 145, 148 149 Amplatz devices for atrial septal defect closure, 42 46 for coronary
More informationTRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO
TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D. THANOPOULOS MD, PhD Associate Professor Agios Loukas Clinic, Thessaloniki, Greece Ares Heart Center, Bucharest, Romania Honorary Consultant,
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More informationPercutaneous VSD closure
Percutaneous VSD closure Gianfranco Butera San Donato Milanese - Italy Patients selection Pts having hemodynamically significant VSD Left ventricular enlargement (left ventricular overload),defined as
More informationAtrial septal defects (ASDs) are one of the most
Transcatheter Closure of Atrial Septal Defects An update on ASD occlusion devices. BY VICTOR-XAVIER TADROS, MD, MSc, AND ANITA W. ASGAR, MD, FRCPC, FACC Atrial septal defects (ASDs) are one of the most
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationAntithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki
Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from
More informationPatient Information. Atrial Septal Defect (ASD) Repair
Patient Information Atrial Septal Defect (ASD) Repair Table of Contents Overview................................. 4 Symptoms................................ 5 Causes..................................
More informationInterventions in Adult Congenital Heart Disease: Role of CV Imaging. Associate Professor. ACHD mortality. Pillutla. Am Heart J 2009;158:874-9
Interventions in Adult Congenital Heart Disease: Role of CV Imaging Sangeeta Shah MD, FACC, FASE Associate Professor ACHD mortality Pillutla. Am Heart J 2009;158:874-9 Adult Congenital Heart Disease Heterogenity
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ
ΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ European Accreditation in TTE, TEE and CHD Echocardiography NOTHING TO DECLARE ATRIAL SEPTAL DEFECT TYPES SECUNDUM
More informationPFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander?
PFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander? J Thompson Sullebarger, M.D. Florida Cardiovascular Institute University of South Florida Kris Letang Tedy Bruschi Bret Michaels The Atrial
More informationARRHYTHMIAS AND DEVICE THERAPY
Topic List A BASICS 1 History of Cardiology 2 Clinical Skills 2.1 History Taking 2.2 Physical Examination 2.3 Electrocardiography 2.99 Clinical Skills - Other B IMAGING 3 Imaging 3.1 Echocardiography 3.2
More informationAMPLATZER Septal Occluder Structural Heart Therapy. Over 15 years of. Demonstrated. Clinical Experience. We ll show you our data. Ask to see theirs.
AMPLATZER Septal Occluder Structural Heart Therapy Over 15 years of Demonstrated Clinical Experience We ll show you our data. Ask to see theirs. Leading the Standard of Care 1,2 The AMPLATZER Septal Occluder
More informationAMPLATZER Septal Occluder
AMPLATZER Septal Occluder A Patient s Guide to the Non-Surgical Closure of the Atrial Septal Defect Using the AMPLATZER Septal Occluder System leadership through innovation TM AGA Medical Corporation 5050
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACHD. See Adult congenital heart disease (ACHD) Adult congenital heart disease (ACHD), 503 512 across life span prevalence of, 504 506
More informationHybrid Muscular VSD Closure in Small Weight Children
Hybrid Muscular VSD Closure in Small Weight Children Shakeel A Qureshi, on behalf of: John P. Cheatham, MD George H. Dunlap Endowed Chair in Interventional Cardiology Director Cardiac Catheterization &
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationTranscatheter Atrial Septal Defect Closure with Right Aortic Arch Is it really difficult? M Tokue, H Hara, K Sugi, M Nakamura
5th Asia Pacific Congenital & Structural Heart Intervention Symposium 2014 10 12 October 2014, Hong Kong Convention and Exhibition Centre Organizer: Hong Kong Society of Congenital & Structural Heart Disease
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of percutaneous closure of patent foramen ovale for the secondary prevention
More informationDevice Closure of ASD in Children Using the Amplatzer Devices: Indications and catheter preparations, technique, and outcome [15]
Device Closure of ASD in Children Using the Amplatzer Devices: Indications and catheter preparations, technique, and outcome [15] SCAI Fellow Course Fall 2014 Ralf J Holzer MD MSc FSCAI Medical Director
More informationΓεώργιος Δ. Κατσιμαγκλής. Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ
Γεώργιος Δ. Κατσιμαγκλής Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ I have no disclosures ΣΥΧΝΟΤΗΤΑ An atrial septal defect (ASD) is a deficiency of the atrial septum.
More informationNON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND
NON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND TOPICS ATRIAL SEPTAL DEFECT VSD IHSS PERCUTANEOUS AORTIC VALVE PERCUTANEOUS MITRAL VALVE
More informationWhen to close an Atrial Septal Defect (ASD) in adulthood?
When to close an Atrial Septal Defect (ASD) in adulthood? Philippe ALDEBERT Hôpital de la Timone, CHU Marseille Département de cardiologie pédiatrique et congénitale médico-chirurgical Abbott Incidence
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationPerventricular Closure of Muscular VSD
Perventricular Closure of Muscular VSD John P. Cheatham, MD, MSCAI George H. Dunlap Endowed Chair in Interventional Cardiology Co-Director, The Heart Center, Nationwide Children s Hospital Professor, Pediatrics
More informationExplantation of Patent Foramen Ovale Closure Devices
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 5, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.01.009 Explantation
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationUptofate Study Summary
CONGENITAL HEART DISEASE Uptofate Study Summary Acyanotic Atrial septal defect Ventricular septal defect Patent foramen ovale Patent ductus arteriosus Aortic coartation Pulmonary stenosis Cyanotic Tetralogy
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationValvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.
Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationEndocarditis and Its Complications: The Role of Echocardiography
Endocarditis and Its Complications: The Role of Echocardiography Pravin Patil, MD FACC FASE Associate Professor of Medicine Director, Cardiovascular Disease Training Program Lewis Katz School of Medicine
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationCase # 1. Page: 8. DUKE: Adams
Case # 1 Page: 8 1. The cardiac output in this patient is reduced because of: O a) tamponade physiology O b) restrictive physiology O c) coronary artery disease O d) left bundle branch block Page: 8 1.
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationInfective Endocarditis عبد المهيمن أحمد
Infective Endocarditis إعداد : عبد المهيمن أحمد أحمد علي Infective endocarditis Inflammation of the heart valve or endocardium of the heart. The agents are usually bacterial, but other organisms can also
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationClinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device The clinical data used to support the CE marking of the Ultraseal LAA Closure device comes from three sources.
More information7. Echocardiography Appropriate Use Criteria (by Indication)
Criteria for Echocardiography 1133 7. Echocardiography Criteria (by ) Table 1. TTE for General Evaluation of Cardiac Structure and Function Suspected Cardiac Etiology General With TTE 1. Symptoms or conditions
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationImportant Safety Information
Important Safety Information Edwards SAPIEN 3 Transcatheter Heart Valve with the Edwards Commander Delivery System Indications: The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and the Society
More informationWhy Should We Treat PFO?
Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course December 7, 2012 Jonathan Tobis, MD Director of Interventional Cardiology UCLA Disclosures Jonathan Tobis, MD 1. A Principal Investigator
More informationApril 16, 09:00-09:15 중앙대학교 윤신원
April 16, 09:00-09:15 중앙대학교 윤신원 When to perform Echocardiography in IE? Vegetations?(pathologic Whatever the level hallmark) of suspicion Intracardiac abscess? Confirm or R/O at the Earliest opportunity.
More informationInfectious complications of new cardiovascular devices Emanuele Durante Mangoni, MD PhD
Infectious complications of new cardiovascular devices Emanuele Durante Mangoni, MD PhD Naples, Italy Disclosure of potential conflicts of interest Emanuele Durante Mangoni, MD PhD My Institution has received
More informationMultifenestrated Septal Occluder Cribriform
Multifenestrated Septal Occluder Cribriform Instructions for Use Device Description The AMPLATZER Multifenestrated Septal Occluder Cribriform (Cribriform Occluder) is a self-expanding double-disc nitinol
More informationThe Patent Foramen Ovale A Preventable Stroke Etiology?! Brian Whisenant, M.D.
The Patent Foramen Ovale A Preventable Stroke Etiology?! Brian Whisenant, M.D. Conflict of Interest Statement I have a financial interest in Coherex Medical. Heart Disease and Stroke Statistics 2008 Update:
More informationAtrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationIntracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications
Eur J Echocardiography (2005) 6, 92e96 Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications Thomas Bartel a, *, Thomas Konorza a, Ulrich Neudorf b, Tiko
More informationTranscatheter Closure of Septal Defects
Transcatheter Closure of Septal Defects Policy Number: 2.02.09 Last Review: 11/2018 Origination: 3/2007 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of mitral leaflets, 80 Accucinch Annuloplasty system, for mitral regurgitation, 79, 94 95 Accutrak delivery system, for CoreValve
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationClinical material and methods. Fukui Cardiovascular Center, Fukui, Japan
Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui
More informationKawasaki Disease: What you need to know from the 2017 Guidelines
Kawasaki Disease: What you need to know from the 2017 Guidelines S. Kristen Sexson Tejtel, MD, PhD, MPH Pediatric Preventive Cardiology TCHAPP Conference April 4, 2019 No disclosures to report Outline
More informationPercutaneous VSD closure: Problems in the mid- and long-term
Percutaneous VSD closure: Problems in the mid- and long-term Lee Benson MD Professor Pediatrics (Cardiology) Director, Cardiac Diagnostic & Interventional Unit The Hospital for Sick Children Toronto, Canada
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationAnaesthesia for percutaneous closure of atrial septal defects Patrick A Calvert BCh MA MRCP Andrew A Klein MBBS FRCA
Anaesthesia for percutaneous closure of atrial septal defects Patrick A Calvert BCh MA MRCP Andrew A Klein MBBS FRCA Key points Percutaneous closure is the procedure of choice for the majority of patients
More informationPercutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder.
Percutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder. First case with a novel delivery system. Werner Budts, Md, PhD, FESC Congenital and Structural Cardiology University
More informationCryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationPercutaneous Closure of Atrial Septal Defects in Patients with an Aberrant Retroaortic Coronary Artery: Is It Safe?
1 CASE REPORT Percutaneous Closure of Atrial Septal Defects in Patients with an Aberrant Retroaortic Coronary Artery: Is It Safe? Alejandro Peirone, MD, FSCAI,* Alejandro Contreras, MD, Pedro Zangroniz,
More informationAMPLATZER Left Atrial Appendage Occluder. A Patient s Guide to the Non-surgical Closure of the Left Atrial Appendage
AMPLATZER Left Atrial Appendage Occluder A Patient s Guide to the Non-surgical Closure of the Left Atrial Appendage This brochure is intended to provide you with general information about the non-surgical
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationLeft Atrial Appendage Closure: The Good, The Bad and The Ugly
Left Atrial Appendage Closure: The Good, The Bad and The Ugly John D. Hummel, MD Director of Electrophysiology Research Ross Heart Hospital, The Ohio State University Columbus, Ohio USA Disclosures Modest
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationPERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt
More informationStructural Heart Disease Patient Guide. Guide contents: 2 What Is Structural Heart Disease? 2 What Happens During Structural Heart Disease?
Guide contents: 2 What Is Structural Heart Disease? 2 What Happens During Structural Heart Disease? 3 Diagnosis 3 Treatment Options 4 Managing the Condition 5 Surgery and Insurance 6 Symptom Tracker Form
More informationGender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences
Gender Differences in Valvular Heart Disease Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Obstacles Interest in gender differences is a relatively new phenomenon Registries/RCT
More informationTranscatheter Closure of Cardiovascular Defects
Medical Coverage Policy Effective Date...11/15/2017 Next Review Date...11/15/2018 Coverage Policy Number... 0011 Transcatheter Closure of Cardiovascular Defects Table of Contents Related Coverage Resources
More information2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction
Summary of Expert Consensus Statement for CLINICIANS 2017 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device Lead Management and Extraction This is a summary of the Heart Rhythm
More informationDISCLOSURE. Echocardiography in Systemic Diseases: Questions. Relevant Financial Relationship(s) None. Off Label Usage None 5/7/2018
Echocardiography in Systemic Diseases: Questions Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate
More informationDescription. Page: 1 of 23. Closure Devices for Patent Foramen Ovale and Atrial Septal Defects. Last Review Status/Date: December 2014
Last Review Status/Date: December 2014 Page: 1 of 23 Description Background Patent Foramen Ovale The foramen ovale, a component of fetal cardiovascular circulation, consists of a communication between
More informationA National Cardiogenic Shock Initiative (CSI):
A National Cardiogenic Shock Initiative (CSI): Insights from the Impella Quality (IQ) Program, cvad Registry and the Detroit CSI Experience William O Neill, MD, FACC Medical Director Structural Heart Disease
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationImplantation of Cardioverter Defibrillator After Percutaneous Closure of Atrial Septal Defect
The Ochsner Journal 10:27 31, 2010 f Academic Division of Ochsner Clinic Foundation Implantation of Cardioverter Defibrillator After Percutaneous Closure of Atrial Septal Defect Anas Bitar, MD, Maria Malaya
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More information